C-RAD AB |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 38.9 SEK | +2.91% |
|
+1.30% | -7.58% |
| May. 04 | RaySearch Laboratories AB and C-RAD Sign Collaboration Agreement | CI |
| Apr. 24 | C-Rad AB Appoints Mats Thorén as Board Member | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 49% by 2026.
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The company returns high margins, thereby supporting business profitability.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- The company appears highly valued given the size of its balance sheet.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -7.58% | 118M | C | ||
| +7.84% | 218B | B | ||
| +7.35% | 184B | B- | ||
| +13.04% | 135B | B- | ||
| -1.37% | 62.38B | A- | ||
| +11.80% | 51.37B | B+ | ||
| +4.81% | 50.9B | B+ | ||
| +0.30% | 40.87B | A | ||
| +2.78% | 36.28B | - | ||
| +26.14% | 31.88B | B+ |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- CRAD B Stock
- Ratings C-Rad AB